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Patient-reported outcomes of adults 
with congenital heart disease from 
eight European countries: scrutinising 
the association with healthcare system 
performance
Liesbet Van Bulck1, Koen Luyckx2,3, Eva Goossens1,4,5,  
Silke Apers1, Adrienne H Kovacs6,7, Corina Thomet8,  
Werner Budts5,9, Maayke A Sluman10,11,12, Katrine Eriksen13, 
Mikael Dellborg14,15,16, Malin Berghammer14,17, Bengt Johansson18, 
Maryanne Caruana19, Alexandra Soufi20, Edward Callus21,22  
and Philip Moons1,23,24 on behalf of the APPROACH-IS 
consortium and the International Society for Adult Congenital 
Heart Disease (ISACHD)
Abstract
Background: Inter-country variation in patient-reported outcomes of adults with congenital heart disease has been 
observed. Country-specific characteristics may play a role. A previous study found an association between healthcare 
system performance and patient-reported outcomes. However, it remains unknown which specific components of the 
countries’ healthcare system performance are of importance for patient-reported outcomes.
Aims: The aim of this study was to investigate the relationship between components of healthcare system performance 
and patient-reported outcomes in a large sample of adults with congenital heart disease.
Methods: A total of 1591 adults with congenital heart disease (median age 34 years; 51% men; 32% simple, 48% 
moderate and 20% complex defects) from eight European countries were included in this cross-sectional study. The 
following patient-reported outcomes were measured: perceived physical and mental health, psychological distress, health 
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behaviours and quality of life. The Euro Health Consumer Index 2015 and the Euro Heart Index 2016 were used as 
measures of healthcare system performance. General linear mixed models were conducted, adjusting for patient-specific 
variables and unmeasured country differences.
Results: Health risk behaviours were associated with the Euro Health Consumer Index subdomains about patient rights 
and information, health outcomes and financing and access to pharmaceuticals. Perceived physical health was associated 
with the Euro Health Consumer Index subdomain about prevention of chronic diseases. Subscales of the Euro Heart 
Index were not associated with patient-reported outcomes.
Conclusion: Several features of healthcare system performance are associated with perceived physical health and health 
risk behaviour in adults with congenital heart disease. Before recommendations for policy-makers and clinicians can be 
conducted, future research ought to investigate the impact of the healthcare system performance on outcomes further.
Keywords
Healthcare system performance, heart defect, congenital, health services accessibility, patient reported outcome 
measures
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Introduction
As a result of an increased life expectancy, the population 
of adults with congenital heart disease (CHD) is growing 
exponentially.1, 2 As a consequence, increased healthcare 
use has been observed, placing an additional burden on 
current healthcare systems worldwide.3 Hence, healthcare 
systems across countries are challenged to meet the needs 
of this patient population, and more specifically, to reach 
satisfactory outcomes in adults with CHD.4 As a result of 
increasing attention for person-centred and comprehensive 
care, interest in assessing patient-reported outcomes 
(PROs) is mounting.5, 6 PROs are ‘measurements based on 
a report that comes directly from the patient about the sta-
tus of a patient’s health condition, without amendment or 
interpretation of the patient’s response by a clinician or 
anyone else’.7 PROs have been shown to be of clinical sig-
nificance, as they are independent predictors of mortality, 
cardiovascular events, hospitalisation and costs of care in 
cardiovascular patient populations.8, 9
Prior research has demonstrated a substantial inter-
country variation in PROs of adults with CHD around the 
world.10 For example, samples of patients from Australia 
had a mean quality of life of 82.1 on the linear analogue 
scale (0–100) and a sample from Japan had a score of 
71.6.11 It has already been demonstrated that patient char-
acteristics, such as sex, age, educational level and New 
York Health Association (NYHA) class partly explain 
variation in PROs.10, 11 At a country-level, standard of liv-
ing and healthcare system characteristics are known pre-
dictors of PROs in adults with CHD.10 One of these studies 
indicated that overall healthcare system performance, as 
measured by World Health Organization (WHO), was 
associated with the perceived health of adults with CHD. 
In general, policy-makers and healthcare administrators 
are increasingly interested in assessing the performance of 
their healthcare systems.12 Measuring performance is 
important to identify high and low-quality service 
delivery, to design healthcare system reforms, to protect 
patients and payers, and to decide on appropriate invest-
ments, all with the overarching goal of improving quality 
of care.12 Access to care, a component of the overall 
healthcare system performance, is an important variable 
that has been associated with healthcare financing and 
outcomes.13
The Andersen behavioural model of health services use 
is a theoretical framework that was developed in the late 
1960s, aiming to facilitate the understanding of which fac-
tors influence patients’ use of healthcare services.14 With 
the growth of supporting empirical evidence, this model 
has expanded.15 In the latest version of the model (see 
Figure 1), healthcare system organisation, including perfor-
mance of the healthcare system, is considered to be a con-
textual characteristic that determines healthcare use and 
patient outcomes.15 Indeed, the model assumes that contex-
tual characteristics at the macro level are both directly and 
indirectly associated with patient outcomes (i.e. perceived 
health and quality of life) and that these relationships can 
be bidirectional. Little research has been undertaken, to 
date, to confirm this presumed relationship.
In recent decades, international agencies (e.g. WHO, 
Organization for Economic Co-operation and Development 
(OECD) and Health Consumer Powerhouse) have made 
efforts to capture and compare the overall performance of 
the healthcare systems of different countries. However, it 
remains unknown which components of countries’ health-
care system performance are associated with PROs in 
adults with CHD. Therefore, in this study we aimed to 
investigate the relationship between components of health-
care system performance and PROs in adults with CHD.
Methods
The present study is part of a larger project entitled 
‘Assessment of Patterns of Patient-Reported Outcomes in 
Adults with Congenital Heart disease – International 
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Study’ (i.e. APPROACH–IS). This research project 
included 4028 adults with CHD from 15 countries com-
prising five continents around the globe.10, 11, 16 For the cur-
rent analyses, we included all European countries 
participating in APPROACH–IS: Belgium, France, Italy, 
Malta, Norway, Sweden, Switzerland and The Netherlands, 
because uniform indices of performance of European 
healthcare systems (i.e. Euro Health Consumer Index 
(EHCI)17 and Euro Heart Index (EHI))18 were available for 
these countries.
Patients were eligible if they met the following criteria: 
(a) diagnosis of CHD, defined as ‘a structural abnormality 
of the heart and/or intra-thoracic great vessels that is pre-
sent at birth and of actual or potential functional signifi-
cance’;19 (b) aged 18 years or older; (c) CHD diagnosis 
established before the age of 10 years (i.e. to warrant suf-
ficient experience of living with CHD); (d) continued fol-
low-up at a CHD centre or included in a national/regional 
CHD registry; and (e) possessing physical, cognitive and 
language capabilities required to complete self-reported 
questionnaires. Exclusion criteria were: (a) prior heart 
transplantation and (b) idiopathic pulmonary arterial 
hypertension.16 Eligible patients received a questionnaire 
package by mail or during an outpatient clinic visit. Data 
collection ran from April 2013 to March 2015. The ration-
ale, design and methods of APPROACH–IS have been 
detailed in a previous paper.16
The study was approved by the institutional review 
board of the university hospitals Leuven/KU Leuven 
Belgium (the coordinating centre) as well as the local insti-
tutional review boards of participating centres when 
required. All participants provided written informed con-
sent to participate. The investigation conforms with the 
principles outlined in the Declaration of Helsinki.20
Measures
Data on four domains of PROs were assessed using self-
report questionnaires: (a) perceived physical and mental 
health status using the 12-item Short Form Health Survey;21 
(b) psychological distress using the Hospital Anxiety and 
Depression Scale;22 (c) health behaviours using the Health 
Behaviour Scale – Congenital Heart Disease;23 and (d) 
quality of life using a linear analogue scale. Further details 
on the measures and their psychometric properties can be 
found online in the Supplementary material (Supplementary 
Table 1).
Healthcare system performance
Healthcare system performance of the participating coun-
tries was operationalised using the EHCI 201517 and the 
EHI 2016,18 both developed by the Health Consumer 
Powerhouse.
The EHCI, which is published annually, measures and 
ranks the performance of healthcare provision of 35 
European countries.17 This index consists of a set of 48 
indicators, which are divided into six subdomains: (a) 
patients’ rights and information; (b) accessibility; (c) out-
comes; (d) range and reach of services provided; (e) pre-
vention; and (f) pharmaceuticals. More information about 
these subdomains can be found in Supplementary Table 2. 
Figure 1. Andersen behavioural model of health services use, sixth revision.15 Permission for reproduction was obtained from 
John Wiley and Sons.
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The performance of the respective national healthcare sys-
tems were graded on a three-grade scale for each of the 48 
indicators (i.e. inadequate, moderate, good) and in line with 
the grading, scores were assigned (i.e. inadequate/not avail-
able = 1, moderate = 2, good = 3). In order to calculate 
the score of each subdomain, the scores assigned to each 
indicator were summed up. Afterwards, the subdomain 
scores were multiplied by fixed weight coefficients and 
added up to make the final country score. As data collection 
ran from 2013 to 2015, we chose to use the EHCI of 2015.
The EHI, which was published in 2008 and 2016, 
focuses specifically on the performance of care provided to 
patients with cardiovascular conditions in 30 European 
countries.18 This index was chosen because adults with 
CHD are primarily treated in cardiovascular care settings. 
The EHI consists of a set of 31 healthcare system perfor-
mance indicators, which are divided into four subdomains: 
(a) prevention; (b) procedures; (c) access to care; and (d) 
outcomes (Supplementary Table 2). Scores on subdomains 
and total score were calculated in a similar way as the 
EHCI. For the present study, we employed the EHI of 2016.
Statistical analyses
Demographic and medical background variables were cal-
culated as median and interquartile range in the case of 
non-normally distributed continuous variables, and as 
absolute numbers and percentages in the case of categori-
cal variables.
Multivariable and sensitivity analyses using general 
linear mixed models were used to estimate the associa-
tion between the domains and total score of healthcare 
system performance (i.e. EHCI and EHI) and five PROs 
(i.e. perceived physical functioning, perceived mental 
health, psychological distress, health risk behaviour and 
quality of life). A two-level structured analysis was used, 
considering that patients were nested within countries. In 
the multivariable analyses, we controlled for patient 
characteristics (i.e. age, sex, educational level, employ-
ment status, marital status, patient-reported NYHA 
assessment and disease complexity) and unmeasured 
country differences (random effect). As all domains of 
the EHCI and EHI were analysed separately, a total of 60 
multivariable analyses were performed. Hence, we 
adjusted for multiple testing by calculating false discov-
ery rates and reporting Benjamini–Hochberg adjusted P 
values. The significance level of the false discovery rate 
was 0.05. In order to evaluate the robustness of the 
results, we performed sensitivity analyses in which we 
left out countries with an outlying value of more than two 
standard deviations (SD) from the mean on one of the 
subdomains of the EHCI or EHI.
Only patients for whom full data were available for all 
variables of interest were included in the general linear 
mixed models, as only a small proportion of patients had 
missing values for PROs (0.0–2.1%) and patient-related 
predictors (0.0–2.5%). The EHCI and EHI possessed com-
plete data. Data analysis was performed using IBM SPSS 




A total of 1591 adults with CHD with full data from eight 
European countries were included in the study. The major-
ity of patients were men (50.7%), had a moderate disease 
complexity (48.0%) and self-reported to be in NYHA class 
I (58.8%) (Table 1).
Table 1. Demographic and medical background variables in 
1591 adults with congenital heart disease in Europe.
Variables n (%)
Men 806 (50.7%)
Median age in years 34 (Q1=26; Q3=45)
Educational level
 Less than high school 98 (6.1)
 High school 778 (48.9)
 College degree 270 (17.0)
 University degree 445 (28.0)
Employment status
 Part-time or full-time work 1122 (70.5)
  Job seeking, unemployed, or 
disabled
177 (11.1)
 Homemaker or retired 112 (7.0)
 Full-time student 87 (5.5)
 Other 93 (5.9)
Marital status
 Married or living with partner 955 (60.0)
 Never married 556 (35.0)
 Divorced or widowed 80 (5.0)
Children: yes 735 (46.2)
Patient-reported New York Heart Association assessment
 Class I 935 (58.8)
 Class II 516 (32.4)
 Class III 104 (6.5)
 Class IV 36 (2.3)
Complexity of heart defect
 Simple 511 (32.1)
 Moderate 763 (48.0)
 Complex 317 (19.9)
Country
 Belgium 261 (16.4)
 France 86 (5.4)
 Italy 51 (3.2)
 Malta 108 (6.8)
 Norway 164 (10.3)
 Sweden 435 (27.3)
 Switzerland 251 (15.8)
 The Netherlands 235 (14.8)
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Healthcare system performance
Scores on the different domains of the EHCI and EHI for 
the respective participating countries are presented on the 
heat map of Figure 2. Looking at the performance of the 
healthcare system (i.e. EHCI), the healthcare system of 
The Netherlands was found to have the best total score, 
followed by Switzerland and Norway. Malta had the low-
est total score. When looking at subdomains, Norway and 
The Netherlands gathered the highest score on ‘patient 
rights and information’. The lowest waiting times were 
observed in Belgium and Switzerland. Best health out-
comes were measured in The Netherlands, Norway, and 
Switzerland, whereas ‘range and reach of services’ was 
found to be best in The Netherlands and Sweden. Norway 
was leading when looking at indicators about prevention 
of chronic diseases. Finally, The Netherlands achieved 
best scores on consumption, financing and deployment of 
pharmaceuticals.
Regarding the performance of cardiovascular care and 
treatment (i.e. EHI) for the respective included countries, 
France had the highest total score, followed by Norway 
and Sweden. In line with the EHCI, the Maltese healthcare 
system performed lowest on cardiovascular care. When 
examining subdomains, Italy performed best on ‘preven-
tion for cardiovascular disease’. France and The 
Netherlands were ranked highest with respect to the sub-
domain ‘quality and availability of procedures concerning 
cardiovascular disease’. Access to cardiovascular care was 
best in France, The Netherlands, Norway and Sweden. 
Finally, Sweden had the best outcomes for cardiovascular 
disease patients.
Patient-reported outcomes
PROs of this patient population were detailed on the heat 
map (Figure 2). Perceived physical and mental health 
scores were highest in patients from Malta. Patients from 
The Netherlands showed the lowest symptoms of psycho-
logical distress. Participants from Sweden had the lowest 
health risk scores, and patients from Switzerland achieved 
the best results on quality of life.
Association between healthcare system 
performance and PROs
Adjusting for patient characteristics, unmeasured country 
differences and multiple testing, the multivariable general 
linear mixed models showed that less risky health behav-
iours were associated with better scores on subdomains 
‘patient rights and information’, ‘outcomes’, or ‘pharma-
ceuticals’, measured by the EHCI (Table 2). Furthermore, 
perceived physical health was associated with healthcare 
systems performing high on the prevention of chronic dis-
eases, as assessed by the EHCI (Table 2). Components of 
Figure 2. Distribution (heat map) of the patient-reported outcomes (PROs) and scores on Euro Health Consumer Index and Euro 
Heart Index of the included European countries. PROs are described as mean (standard deviation).
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the EHI were not associated with PROs in adults with 
CHD.
Because Malta had outlying values (>2 SD) on the 
EHCI subdomain ‘outcomes’ and the EHI subdomain ‘pre-
vention’, we repeated these analyses while excluding the 
data from Malta. After correction for false discovery rate, 
the associations between EHCI subdomain ‘outcomes’ and 
PROs did not change, as again only the association between 
the subdomain ‘outcomes’ and the total health risk score 
was significant. Again, no significant associations were 
found between the EHI subdomain ‘prevention’ and PROs.
Discussion
We examined associations between components of the 
healthcare system performance and PROs in adults with 
CHD, in order to scrutinise further geographical differ-
ences in PROs that were previously reported.10 Health risk 
behaviours of adults with CHD were found to be associated 
with the EHCI subdomains ‘outcomes’, ‘patient rights and 
information’ and ‘pharmaceuticals’. Physical health status 
was associated with the EHCI subdomain ‘prevention’.
The relationship between health risk behaviours and 
‘outcomes’ is perhaps unsurprising because the EHCI 
subdomain ‘outcomes’ comprises indicators particularly 
relevant for patients with CHD, such as a decrease of car-
diovascular disease deaths, decrease of stroke deaths and 
infant deaths.17 It is well known that a heart-healthy life-
style is associated with favourable health outcomes, both 
in the general and in clinical populations.24
The subdomain ‘patient rights and information’ pertains 
to the ability of a healthcare system to provide the patients 
with a status strong enough to be able to interpret informa-
tion in an appropriate manner. Hence, a high score on 
‘patient rights and information’ reflects the importance that 
is given to inform and instruct patients in particular coun-
tries. In its turn, this may have resulted in patients with 
higher patient activation, who are willing and able to take 
charge of their own health by performing good health 
behaviours.25 Indeed, patient activation and empowerment 
have been shown to be associated with healthy behaviour.26
The EHCI subdomain ‘pharmaceuticals’ describes con-
sumption, financing and access to drugs. It can be pre-
sumed that countries with good access and refunds for 
pharmaceuticals have good access and refunds for other 
healthcare services as well. Indeed, this might partly 
explain the association found between the EHCI subdo-
main ‘pharmaceuticals’ and health risk behaviours.
Table 2. Multivariable general linear mixed models with Euro Health Consumer Index and Euro Heart Index healthcare system 











Euro Health Consumer Index
Patient rights and information 0.01 (0.05) −0.01 (0.04) −0.04 (0.01) −0.24 (0.06) 0.005 (0.04)
Accessibility −0.04 (0.01) −0.01 (0.01) 0.005 (0.007) 0.01 (0.04) 0.0006 (0.01)
Outcomes 0.01 (0.03) −0.006 (0.02) −0.02 (0.008) −0.14 (0.02) 0.01 (0.02)
Range and reach of services provided 0.01 (0.05) −0.002 (0.04) −0.01 (0.02) −0.15 (0.09) −0.06 (0.04)
Prevention 0.31 (0.04) 0.13 (0.06) −0.09 (0.03) −0.38 (0.21) 0.04 (0.08)
Pharmaceuticals −0.02 (0.07) −0.05 (0.06) −0.03 (0.03) −0.37 (0.09) −0.02 (0.06)
Total score −0.007 (0.01) −0.006 (0.008) −0.004 (0.004) −0.05 (0.01) −0.0001 (0.008)
Euro Heart Index
Prevention −0.03 (0.04) −0.05 (0.02) −0.009 (0.01) −0.10 (0.07) −0.004 (0.03)
Procedures −0.02 (0.03) −0.05 (0.02) −0.003 (0.01) −0.08 (0.06) −0.006 (0.03)
Access to care 0.05 (0.05) −0.02 (0.04) −0.02 (0.02) −0.16 (0.09) 0.03 (0.04)
Outcomes −0.001 (0.03) −0.03 (0.02) 0.007 (0.01) −0.07 (0.05) −0.02 (0.02)
Total score −0.003 (0.01) −0.02 (0.008) −0.0007 (0.004) −0.04 (0.02) −0.003 (0.009)
Values in table are estimates (standard error).
Colour-coding refers to significance of estimate after correction for multiple testing (Benjamini–Hochberg adjusted P value).
Physical and mental health status: higher scores reflect better perceived health.
Psychological distress: higher scores reflect more symptoms of depression and anxiety.
Total health risk score: higher scores reflect unhealthier behavior.
Quality of life: higher scores reflect higher quality of life.
NS <0.05 <0.01 <0.001
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The association between perceived physical health and 
the EHCI subdomain ‘prevention’ is anticipated given that 
it is hoped that healthcare systems that focus on prevention 
would help individuals achieve better health status. 
Although our study showed an association between these 
distal concepts, future studies could perhaps add clarity 
about underlying mechanisms and possible confounders.
Subdomains of the EHCI that were not related to any 
of the PROs were ‘accessibility of care’ and the ‘range 
and reach of services provided’. This suggests that the 
general accessibility of healthcare and a broad offer of 
public services in the respective countries may not reflect 
PROs in CHD. Moreover, healthcare system performance 
only seems to be of importance for physical wellbeing and 
health risk behaviours. No associations have been found 
with perceived mental health, psychological distress and 
quality of life.
Regarding the EHI, none of the subdomains were 
associated with PROs of adults with CHD. Even when 
excluding the outlying value of Malta on the EHI subdo-
main of prevention in sensitivity analyses, no significant 
association was found. As associations with EHI domains 
were expected, these results are surprising. To the best of 
our knowledge, this is the first time that the EHI has been 
used for research. In order to be able to interpret the 
absence of associations, the relevance of the index for 
congenital as well as for acquired heart diseases should 
be investigated.
Methodological issues
First, we performed an explorative ecological cross-sec-
tional study. Hence, no conclusions in terms of the direc-
tion of effects or causality can be drawn. Indeed, the field 
of PRO research would benefit from longitudinal assess-
ment.27 Moreover, we could not assess the underlying 
mechanisms, which is why we are unable to provide expla-
nations of observed associations.
Second, we measured the components of healthcare sys-
tem performance using the EHCI and the EHI.17, 18 These 
measures deliver very detailed information on the subdo-
mains of healthcare system performance of the participating 
countries. Although some individuals have criticised these 
performance measures on their transparency, methodology 
and validity,28, 29 we are unaware of any better measures of 
components of healthcare system performance.
Third, data of healthcare system performance were 
gathered on a country level and PROs were gathered on a 
patient level. However, multilevel analyses were per-
formed to control for unmeasured country differences and 
to consider that patients are nested in countries.
Fourth, it is difficult to tell to what extent our findings 
can be generalised. Although the differences in demo-
graphic, clinical and health status characteristics between 
participants and non-participants appeared to be small,30 the 
present study included eight European countries, all of 
which were high-income countries. It would be interesting 
to include middle-income European countries (e.g. Albania, 
Croatia, Macedonia and Kosovo) in future studies and to 
investigate the effect of the general healthcare system per-
formance on PROs beyond the European borders. Moreover, 
the unequal division of participants across the countries 
might also have influenced the results, as some countries 
have been overrepresented with regard to other countries. 
Furthermore, patients who received the questionnaire were 
almost all under follow-up in a CHD/adult CHD centre and 
it could be that patients who are not under follow-up have 
different characteristics. Finally, it remains unknown 
whether our results in adults with CHD can be generalised 
to other patient populations. CHD, as a sample case, repre-
sents a broad spectrum of mild, moderate, and complex 
chronic diagnoses. To increase the generalisability and 
transferability of findings, it would be interesting to add a 
healthy control group or general population normative data.
Generally, the findings of this study provide information 
on which domains of the healthcare system performance 
are of importance for particular PROs of adults with CHD. 
However, further research is needed in order to be able to 
give concrete advice for policy-makers or for clinical prac-
tice. We hope that our present findings may be a trigger for 
future research to fill these knowledge gaps.
Conclusion
The current study showed that several features of health-
care system performance are associated with perceived 
physical health and health risk behaviours in adults with 
CHD. More specifically, the EHCI subdomains ‘out-
comes’, ‘prevention’, ‘patient rights and information’ and 
‘pharmaceuticals’ were associated with these two PROs, 
above and beyond patient characteristics. Before recom-
mendations for policy-makers can be conceived, future 
research should further investigate the impact of the 
healthcare system performance on outcomes of adults with 
CHD using different indices and should examine the 
underlying mechanisms of the associations found.
Implications for practice
•• ‘Outcomes’, ‘prevention’, ‘patient rights and 
information’, and ‘pharmaceuticals’ are aspects 
of general healthcare system performance that 
may translate into better patient-reported out-
comes of persons with congenital heart disease.
•• Policy-makers should safeguard healthcare system 
factors that are protective for patient outcomes.
•• Countries that score low on particular domains of 
the healthcare system performance could consider 
investing in these features in order to improve 
outcomes of specific patient populations.
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